Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs

Biological Psychiatry

Volumn 63, Issue 4, 2008, Pages 424-434

  Nemeroff, Charles B ^a   Entsuah, Richard ^b   Benattia, Isma ^b   Demitrack, Mark ^b   Sloan, Diane M ^c   Thase, Michael E ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c Advogent   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antidepressants; depression; remission; SSRIs

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; COMPREHENSIVE ANALYSIS OF REMISSION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; REMISSION; SYSTEMATIC REVIEW; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 38349115076     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.06.027     Document Type: Article

References (83)

1. Morris J.B., and Beck A.T. The efficacy of antidepressant drugs: A review of research (1958-1972). Arch Gen Psychiatry 30 (1974) 667-674
2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 4 suppl (2000) 1-45
3. Khan A., Warner H.A., and Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57 (2000) 311-317
4. Walsh B.T., Seidman S.N., Sysko R., and Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002) 1840-1847
5. Thase M.E. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 36 suppl 1 (2002) S1-S17
6. Lieberman J.A., Greenhouse J., Hamer R.M., Krishnan K.R., Nemeroff C.B., Sheehan D.V., et al. Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30 (2005) 445-460
7. Anderson I.M., and Tomenson B.M. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8 (1994) 238-249
8. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 58 (2000) 19-36
9. Anderson I.M. SSRIS versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depress Anxiety 7 suppl 1 (1998) 11-17
10. Nelson J.C., Mazure C.M., Jatlow P.I., Bowers Jr. M.B., and Price L.H. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 55 (2004) 296-300
11. Einarson T.R., Arikian S.R., Casciano J., and Doyle J.J. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin Ther 21 (1999) 296-308
12. Thase M.E., Entsuah A.R., and Rudolph R.I. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178 (2001) 234-241
13. Stahl S.M., Entsuah R., and Rudolph R.L. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biol Psychiatry 52 (2002) 1166-1174
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55
15. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision (1992), WHO, Geneva
16. Nemeroff C.B., and Thase M.E. On behalf of the EPIC 014 Study Group: A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41 (2007) 351-359
17. Schatzberg A., and Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with depression. Am J Geriatric Psychiatry 14 (2006) 361-370
18. Cantillon M, Daley M. Further superiority of SNRI venlafaxine over SSRI fluoxetine in major depression and melancholia: a double-blind, placebo-controlled study of both response and remission (wellness). Poster presented at the First Annual Meeting of the International Forum on Mood and Anxiety Disorders, November 2000; Monte Carlo, Monaco.
19. Data on file. Collegeville, PA: Wyeth Research.
20. Rudolph R., and Feiger A. A double-blind, randomised, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56 (1999) 171-181
21. Clerc G.E., Ruimy P., and Verdeau P.J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. Int Clin Psychopharmacol 9 (1994) 139-143
22. Dierick M., Ravizza L., Realini R., and Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 20 (1996) 57-71
23. Silverstone P.H., and Ravindran A. Once-daily venlafaxine extended-release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 60 (1999) 22-28
24. Rudolph R., Aguiar L., Entsuah R., and Derivan A. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. Eur Neuropsychopharmacol 8 suppl 3 (1998) Abstract P.1.027
25. Keller M., Trivedi M.H., Thase M.E., Shelton R., Kornstein S., Nemeroff C.B., et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: Outcomes from the acute and continuation phases. J Clin Psychiatry 68 (2007) 1246-1256
26. Tzanakaki M., Guazzelli M., Nimatoudis I., Zissis N.P., Smeraldi E., and Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalised patients with major depression and melancholia. Int Clin Psychopharmacol 15 (2000) 29-34
27. Kornaat H. Randomized, double-blind comparison of venlafaxine and fluoxetine for moderately depressed outpatients. Int J Neuropsychopharmacol 3 suppl 1 (1998) Abstract PMK02021
28. Tylee A., Beaumont G., Bowden M.W., and Reynolds A. A double-blind, randomized, 2-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry 3 (1997) 51-58
29. De Nayer A., Geerts S., Ruelens L., Schittecatte M., De Bleeker E., and Van Eeckhoutte I. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5 (2002) 115-120
30. Alves C., Cachola I., and Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry 5 (1999) 57-63
31. Costa-e-Silva J. Randomised, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59 (1998) 352-357
32. Stevens I. Comparison of the efficacy and safety of venlafaxine and fluoxetine in GP patients with moderate to severe depression. Biol Psychiatry 42 suppl 1 (1997) 244s [abstract 90-48]
33. Mehtonen O., and Nordiska A.B. A double-blind, randomized study of the efficacy and safety of venlafaxine extended release (ER) versus fluoxetine in outpatients with major depression. Eur Neuropsychopharmacol 12 suppl 3 (2002) S253 [abstract]
34. Dufour A., Van Hauteghem D., Slachmuylders P., Leyman S., and Mignon A. Clinical acceptability of venlafaxine extended release and paroxetine in outpatients treated for depression by general practitioners. Eur Neuropsychopharmacol 11 suppl 3 (2001) S224 [abstract]
35. Salinas E., and Venlafaxine XR 367 Study Group. Once daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biol Psychiatry 42 suppl 1 (1997) 244s [abstract 90-49]
36. Casabona G.M., Silenzi V., and Guazzelli M. A randomized, double blind, comparison of venlafaxine ER and paroxetine in outpatients with moderate to severe major depression. Eur Neuropsychopharmacol 12 suppl 3 (2002) S208 [abstract]
37. Poirier M.-F., and Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 175 (1999) 12-16
38. Ballus C., Quiros G., De Flores T., de la Torre J., Palao D., Rojo L., et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorders or dysthymia. Int Clin Psychopharmacol 15 (2000) 43-48
39. McPartlin G.M., Reynolds A., Anderson C., and Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 4 (1998) 127-132
40. Mehtonen O., Sogaard J., Roponen P., and Behnke K. Randomised, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 61 (2000) 95-100
41. Allard P., Gram L., Timdahl K., Behnke K., Hanson M., and Sogaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 19 (2004) 1123-1130
42. Lenox-Smith A.J., Schaeffer P., Reynolds A., and Willard L. A double-blind trial of venlafaxine ER vs citalopram in patients with severe depression (2001) Poster presented at Annual Meeting of the British Association for Psychopharmacology, July 5-8, Cambridge, United Kingdom
43. Hackett D., Salinas E., and Desmet A. Efficacy and safety of venlafaxine vs fluvoxamine in outpatients with major depression. Eur Neuropsychopharmacol 8 suppl 3 (1998) abstract 1.210.
44. Benattia I., Musgnung J., and Graepel J. Using treatment algorithms to achieve remission of depression with venlafaxine XR or SSRIs. Int J Neuropsychopharmacol 7 suppl 1 (2004) S167 [abstract P01.129]
45. Diaz-Martinez A., Benassinni O., Ontiveros A., Gonzalez S., Salin R., Basquedano G., and Martinez R.A. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 20 (1998) 467-476
46. Shelton R.C., Haman K.L., Rapaport M.H., Kiev A., Smith W.T., Hirschfeld R.M., et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 67 (2006) 1674-1681
47. Sir A., D'Souza R.F., Uguz S., George T., Vahip S., Hopwood M., et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 66 (2005) 1312-1320
48. Montgomery S.A., MoHuusom A.K., and Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50 (2004) 57-64
49. Bielski R.J., Ventura D., and Chang C.C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65 (2004) 1190-1196
50. Davidson J., Watkins L., Owens M., Krulewicz S., Connor K., Carpenter D., et al. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol 25 (2005) 480-484
51. Hwang J.P., Yang C.H., and Tsai S.J. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Int J Geriatr Psychiatry 19 (2004) 189-190
52. Galecki P., Florkowski A., Pietras T., Kolodziejska I., Nowakowski T., Pawelczyk A., et al. Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients. [in Polish]. Pol Merkuriusz Lek 17 (2004) 621-624
53. Simon J.S., Sheehan D., Thase M., Owens M., Krulewicz M.A., Carpenter D., et al. Comparison of efficacy and tolerability of paroxetine CR versus venlafaxine XR (2005) Poster presented at the Annual Meeting of the American Psychiatric Association, May 20-25, Atlanta, Georgia
54. Vieta E., Martinez-Aran A., Goikolea J.M., Torrent C., Colom F., Benabarre A., et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 63 (2002) 508-512
55. Oslin D.W., Ten Have T.R., Streim J.E., Datto C.J., Weintraub D., DiFilippo S., et al. Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 64 (2003) 875-882
56. Zanardi R., Franchini L., Serretti A., Perez J., and Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study. J Clin Psychiatry 61 (2000) 26-29
57. Dichter G.S., Tomarken A.J., Freid C.M., Addington S., and Shelton R.C. Do venlafaxine XR and paroxetine equally influence negative and positive affect?. J Affect Disord 85 (2005) 333-339
58. Duval S., and Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000) 455-463
59. Egger M., Smith G.D., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
60. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
61. Higgins J., and Thompson S.G. Quantifying heterogeneity in meta-analysis. Statist Med 21 (2002) 1539-1558
62. Cook R.J., and Sackett D.L. The number needed to treat: A clinically useful measure of treatment effect. BMJ 310 (1995) 452-454
63. Kraemer H.C., and Kupfer D.J. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59 (2006) 990-996
64. Khan A., Brodhead A.E., Kolts R.L., and Brown W.A. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 39 (2005) 145-150
65. Rush A.J., Kraemer H.C., Sackeim H.A., Fava M., Trivedi M.H., Frank E., et al., ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31 (2006) 1841-1853
66. Mintz J., Mintz L.I., Arruda M.J., and Hwang S.S. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 49 (1992) 761-768
67. Judd L.L., Akiskal H.S., Zeller P.J., Paulus M., Leon A.C., Maser J.D., and Endicott J. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 57 (2000) 375-380
68. Thase M.E., Simons A.D., McGeary J., Cahalane J.F., Hughes C., Harden T., et al. Relapse after cognitive behavior therapy of depression: Potential implications for longer courses of treatment?. Am J Psychiatry 149 (1992) 1046-1052
69. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., and Barocka A. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 25 (1995) 1171-1180
70. Simon G.E. Long-term prognosis of depression in primary care. Bull World Health Organ 78 (2000) 439-445
71. Thase M.E., Howland R.H., and Friedman E.S. Onset of action of selective and multi-action antidepressants. In: den Boer J.A., and Westenberg H.G.M. (Eds). Antidepressants: Selectivity or Multiplicity? (2001), Benecke, Amsterdam 101-116
72. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90 (1986) 131-138
73. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18 (1990) 289-299
74. Quitkin F.M., Taylor B.P., and Kremer C. Does mirtazapine have a more rapid onset than SSRIs?. J Clin Psychiatry 62 (2001) 358-361
75. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., Detke M.J., Mallinckrodt C., Lu Y., et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36 (2002) 106-132
76. Harvey A.T., Rudolph R.L., and Preskorn S.H. Evidence of the dual action of venlafaxine. Arch Gen Psychiatry 57 (2000) 503-509
77. Bitsios P., Szabadi E., and Bradshaw C.M. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berlin) 143 (1999) 286-292
78. Gilmor M.L., Owens M.J., and Nemeroff C.B. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159 (2002) 1702-1710
79. Buckley N.A., and McManus P.R. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325 (2002) 1332-1333
80. Whyte I.M., Dawson A.H., and Buckley N.A. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96 (2003) 369-374
81. Leverich G.S., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., Keck Jr. P.E., et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163 (2006) 232-239
82. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50 (2001) 345-350
83. Nemeroff C.B. Early-life adversity, CRF dysregulation, and vulnerability to mood and anxiety disorders. Psychopharmacol Bull 38 suppl 1 (2004) 14-20